These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 26864303)

  • 21. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
    Dermani FK; Samadi P; Rahmani G; Kohlan AK; Najafi R
    J Cell Physiol; 2019 Feb; 234(2):1313-1325. PubMed ID: 30191996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-CTLA-4 therapy for malignant mesothelioma.
    Guazzelli A; Bakker E; Krstic-Demonacos M; Lisanti MP; Sotgia F; Mutti L
    Immunotherapy; 2017 Mar; 9(3):273-280. PubMed ID: 28231719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune Checkpoint Inhibitors to Treat Malignant Lymphomas.
    Witkowska M; Smolewski P
    J Immunol Res; 2018; 2018():1982423. PubMed ID: 29850620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New B7 Family Checkpoints in Human Cancers.
    Ni L; Dong C
    Mol Cancer Ther; 2017 Jul; 16(7):1203-1211. PubMed ID: 28679835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune checkpoint blockade therapy: the 2014 Tang Prize in Biopharmaceutical Science.
    Chen YS; Shen CR
    Biomed J; 2015; 38(1):5-8. PubMed ID: 25673064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Programmed death-1 checkpoint blockade in acute myeloid leukemia.
    Sehgal A; Whiteside TL; Boyiadzis M
    Expert Opin Biol Ther; 2015; 15(8):1191-203. PubMed ID: 26036819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
    Zolov SN; Rietberg SP; Bonifant CL
    Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PD-1/PD-L1 Pathway in Breast Cancer.
    Schütz F; Stefanovic S; Mayer L; von Au A; Domschke C; Sohn C
    Oncol Res Treat; 2017; 40(5):294-297. PubMed ID: 28346916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS; Quezada SA; Allison JP
    Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intracellular mechanisms of tumor cells' immunoresistance.
    Hermanowicz J; Sieklucka B; Nosek K; Pawlak D
    Acta Biochim Pol; 2020 Apr; 67(2):143-148. PubMed ID: 32320192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.
    Gorris MAJ; Halilovic A; Rabold K; van Duffelen A; Wickramasinghe IN; Verweij D; Wortel IMN; Textor JC; de Vries IJM; Figdor CG
    J Immunol; 2018 Jan; 200(1):347-354. PubMed ID: 29141863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Characterization of Circulating Tumor Cells to Study Cancer Immunoevasion.
    Nicolazzo C; Gradilone A; Carpino G; Gazzaniga P; Raimondi C
    Methods Mol Biol; 2019; 1884():247-258. PubMed ID: 30465208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
    Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
    Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
    Antonia SJ; Vansteenkiste JF; Moon E
    Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The fusion of quantitative molecular proteomics and immune-oncology: a step towards precision medicine in cancer therapeutics.
    Miles J; Ward SG; Larijani B
    FEBS Lett; 2022 Nov; 596(21):2721-2735. PubMed ID: 36002439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
    Wang SD; Li HY; Li BH; Xie T; Zhu T; Sun LL; Ren HY; Ye ZM
    Int Immunopharmacol; 2016 Sep; 38():81-9. PubMed ID: 27258185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The PD-1/PD-L1 pathway in human pathology.
    Saresella M; Rainone V; Al-Daghri NM; Clerici M; Trabattoni D
    Curr Mol Med; 2012 Mar; 12(3):259-67. PubMed ID: 22300137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of immune checkpoint blockade for brain metastases.
    Harary M; Reardon DA; Iorgulescu JB
    CNS Oncol; 2019 Jun; 8(2):CNS33. PubMed ID: 30854898
    [No Abstract]   [Full Text] [Related]  

  • 40. [Not Available].
    Senant M; Giusti D; Weiss L; Dragon-Durey MA
    Bull Cancer; 2016 Nov; 103 Suppl 1():S175-S185. PubMed ID: 28057182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.